<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303730</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10096</org_study_id>
    <nct_id>NCT02303730</nct_id>
  </id_info>
  <brief_title>Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes</brief_title>
  <official_title>Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Minhang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether exenatide is superior to insulin glargine
      (after 24 weeks) in reducing liver fat content (by MRS) in patients with newly diagnosed type
      2 diabetes mellitus and concomitant non-alcoholic fatty-liver disease(NAFLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, parallel-group, active controlled, multi-center clinical
      trial to investigate whether exenatide is superior to insulin glargine in reducing liver fat
      content in patients with newly diagnosed type 2 diabetes mellitus and concomitant
      NAFLD.Patients with type 2 diabetes and concomitant NAFLD from 18-70 years of age, with
      inadequate glycaemic control defined as 7% ≤ HbA1c ≤ 9% and BMI≥24kg/ m2 at the time of
      screening. Patients should be on diet and exercise but drug treatment naive, no use of any
      glucagon-like peptide-1(GLP-1) analogues or insulin within 3 months before enrolment.Patients
      will have an screening period 2 weeks, and a 24-week open label treatment period.

      All demographic data variables collected by descriptive analysis tests are used. Qualitative
      variables use absolute frequency and percentage, and numeric variables use average, mean,
      median, standard deviation, maximum, minimum, quartiles, etc. Unless specifically stated,
      statistical significance will be defined as P＜0.05 in the whole analysis procedure.For the
      primary endpoint of this study, superiority test will be applied to the quantitative data of
      these two groups. For secondary and exploratory efficacy variables, difference test will be
      used to analyse repeated measurement data from two groups. For essential Safety parameters,
      difference test will be used to analyse the differences between two groups.The analysis of
      all primary and secondary endpoints of efficacy and safety must be based on the Full Analysis
      Set (FAS). As supporting evidence, the analysis of primary endpoint variables must also
      comply with the Pre-protocol (PPS) Analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat content（%） measured by MRS</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in intra-abdominal visceral fat content (cm2), abdominal subcutaneous fat content (cm2), and ratio between intra-abdominal visceral fat and subcutaneous fat area by MRI</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose metabolism (fasting blood glucose, postprandial plasma glucose, HbA1c)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood lipid profile (total cholesterol, triglyceride, HDL, LDL)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight,waist circumference and hip circumference</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in cardiac function measured by echocardiography</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in β-cell function (fasting C-peptide, 2-hour postprandial C-peptide)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in liver enzymes and laboratory parameters (hematology, biochemical tests)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hypoglycaemia events</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events（AEs）and Severe adverse events(SAEs)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine subcutaneously, once daily, for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose&lt;2.9 mmol/l or &lt; 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c &lt;8% use 0.1 -0.2 U/kg per day;HbA1c &gt;8% use 0.2 -0.3 U/kg per day).
Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):
fasting blood glucose(FBG) &gt; 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.
If hypoglycemia, reduce insulin glargine by:
blood glucose &lt;70mg/dl（3.9mmol/l）: 10%-20%; blood glucose &lt;40mg/dl（2.2mmol/l）: 20%-40%.</description>
    <arm_group_label>Insulin glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 ≤ age ≤ 70 years old.

          -  Newly diagnosed type 2 diabetes mellitus (WHO Diagnostic criteria for diabetes
             mellitus, 1999).

          -  Patients with NAFLD, MRS measurement of liver fat content&gt; 10%.

          -  7% ≤ HbA1c ≤ 10%

          -  No heavy drinking history within the last 5 years (alcohol intake: male &lt; 20 g/d,
             female &lt; 10 g/d)

          -  HBsAg (-), hepatitis C virus antibody (HCV-Ab) (-)

          -  BMI ≥ 24 kg/m2;

        Exclusion Criteria:

          -  Pregnancy, lactation, intended pregnancy, or failure to take adequate contraceptive
             measures taken (contraception measures including sterilization, intrauterine device,
             oral contraceptives, and persistent use of condoms).

          -  Type 1 diabetes mellitus, gestational diabetes mellitus or other special types of
             diabetes.

          -  Liver and renal dysfunction (ALT or aspartate aminotransferase(AST) is 2.5 times
             higher than the upper limit of normal, or total bilirubin is 1.5 times higher than the
             upper limit of normal, or Cr ≥ 115 μmol/L).

          -  increased amylase (blood amylase is 2.5 times higher than the upper limit of normal)
             or presence of gastrointestinal disease.

          -  Use of drugs that may affect liver fat content within one month before or during the
             trial period, such as glucocorticoids, thyroid hormone, etc.

          -  Use of GLP-1 receptor agonist, dipeptidyl peptidase -4 (DPP-4) inhibitors or insulin
             within 3 months before enrolment

          -  Presence of serious dyslipidemia or other endocrine diseases (hypothyroidism,
             hypothalamic-pituitary dysfunction, etc).

          -  Fatty liver caused by viral hepatitis, drug, alcohol, Wilson disease or total
             parenteral nutrition.

          -  Presence of liver cancer, infection, biliary tract disease or recently increased liver
             enzyme due to medication.

          -  Participation in strenuous exercise or administration of any drugs that affect glucose
             metabolism.

          -  History of pancreatitis, alcohol abuse, metal disorders or history of allergy to
             investigational drug.

          -  Congestive heart failure defined as New York Heart Association (NYHA) class III or IV,
             unstable angina or myocardial infarction in recent 6 months.

          -  Any situation that may affect the implementation or results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Gao, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Bian, doctor</last_name>
    <phone>13681976102</phone>
    <email>bian.hua@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Liu, master</last_name>
    <phone>18616880860</phone>
    <email>liu.lin@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Gao, doctor</last_name>
      <phone>862164041990</phone>
      <phone_ext>8021</phone_ext>
      <email>gao.xin@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hua Bian, doctor</last_name>
      <phone>13681976102</phone>
      <email>bian.hua@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xin Gao, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hua Bian, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Liu, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism, Shanghai Minhang Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Lin Yang, doctor</last_name>
      <phone>18918169025</phone>
      <email>Jialinyang2002@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism,Huadong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiao Sun, Bachelor</last_name>
      <phone>18621831253</phone>
      <email>sunjiao6972@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism,Shanghai 6th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Qian Bao, Bachelor</last_name>
      <phone>13788971763</phone>
      <email>byq522@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism,Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Quan Shi, master</last_name>
      <phone>13701794075</phone>
      <email>young.stone@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, Wu G, Shi L, Feng Z, Qiu L, Li Q, Guo X, Luo Z, Lu J, Shan Z, Yang W, Ji Q, Yan L, Li H, Yu X, Li S, Zhou Z, Lv X, Liang Z, Lin S, Zeng L, Yan J, Ji L, Weng J. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med. 2015 Jan;277(1):137-50. doi: 10.1111/joim.12293. Epub 2014 Aug 5.</citation>
    <PMID>25039675</PMID>
  </reference>
  <reference>
    <citation>Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010 May;51(5):1584-92. doi: 10.1002/hep.23569.</citation>
    <PMID>20225248</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6(9):e25269. doi: 10.1371/journal.pone.0025269. Epub 2011 Sep 21.</citation>
    <PMID>21957486</PMID>
  </reference>
  <reference>
    <citation>Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010 Mar;23(3):334-9. doi: 10.1038/ajh.2009.245. Epub 2009 Dec 17.</citation>
    <PMID>20019672</PMID>
  </reference>
  <reference>
    <citation>Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7(12):e50117. doi: 10.1371/journal.pone.0050117. Epub 2012 Dec 6.</citation>
    <PMID>23236362</PMID>
  </reference>
  <reference>
    <citation>Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol. 2010 Dec;105(12):2707-9. doi: 10.1038/ajg.2010.363.</citation>
    <PMID>21131943</PMID>
  </reference>
  <reference>
    <citation>Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9.</citation>
    <PMID>21660077</PMID>
  </reference>
  <reference>
    <citation>Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014 Sep;30(6):521-9. doi: 10.1002/dmrr.2561.</citation>
    <PMID>24823873</PMID>
  </reference>
  <reference>
    <citation>Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E829-35. Epub 2006 Nov 7.</citation>
    <PMID>17090752</PMID>
  </reference>
  <reference>
    <citation>ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.</citation>
    <PMID>22686416</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>September 10, 2016</last_update_submitted>
  <last_update_submitted_qc>September 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xin Gao</investigator_full_name>
    <investigator_title>vice-president</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

